Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2): the KLF4 transcription factor has been shown to sustain CML LSCs via downregulation of the dual-specificity kinase DYRK2, that mediates the stabilization of p53 and the proteasomal degradation of c-MYC. The gene discussed is DYRK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.